相关实验视频
Updated: Jul 26, 2025

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
94.6K
补充维生素D可以通过修改IRS-1和PPARγ/NF-κB表达来缓解糖尿病前老鼠的胰岛素抵抗
Desak Gede Budi Krisnamurti1, Melva Louisa2, Erni H Poerwaningsih1
1Department of Medical Pharmacy, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
Frontiers in endocrinology
|June 16, 2023
概括
补充维生素D可以改善糖尿病前老鼠的葡萄糖控制和胰岛素抵抗. 这可能是由于维生素D.
科学领域:
- 内分泌学和新陈代谢学
- 营养科学 营养科学
背景情况:
- 糖尿病前期意味着中间高血糖,这是2型糖尿病的前体.
- 维生素D缺乏经常与胰岛素抵抗和糖尿病发展有关.
- 研究维生素D在减轻糖尿病前期胰岛素抵抗方面的作用至关重要.
研究的目的:
- 为了检查维生素D补充剂对糖尿病前老鼠模型中的胰岛素耐药性的影响.
- 阐明维生素D对胰岛素抵抗作用的潜在机制.
主要方法:
- 在Wistar大鼠中诱导了糖尿病前期,使用高脂肪,高葡萄糖饮食和链毒素.
- 鼠接受了不同剂量的维生素D3 (100 IU/kg或1000 IU/kg) 或没有治疗12周.
- 评估了葡萄糖控制,胰岛素耐药性标志物和关键蛋白质表达 (IRS1,PPARγ,NF-κB).
主要成果:
- 维生素D3补充剂剂量取决于改善葡萄糖控制,降低禁食血糖,改善口服葡萄糖耐受性,降低HOMA-IR.
- 组织学分析显示,用维生素D治疗减少了兰格汉斯变性岛屿.
- 维生素D调节炎症标志物 (IL-6/IL-10比率) 和关键信号通路,降低IRS1和NF-κB酸化,同时增加PPARγ表达.
结论:
- 补充维生素D有效地降低了糖尿病前老鼠的胰岛素抵抗.
- 这些有益的效果很可能是通过调节IRS1,PPARγ和NF-κB途径来实现的.
- 维生素D显示出作为治疗糖尿病前期管理的治疗剂的潜力.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240
Dipeptidyl Peptidase 4 Inhibitors
216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216
Insulin: Dosing Regimen and Adverse Effects
215
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
215
Insulin: The Receptor and Signaling Pathways
1.3K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.3K
Glucagon-like Receptor Agonists
369
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
369
Insulin: Biosynthesis, Chemistry, and Preparation
442
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
442

